Comparative Pharmacology
Head-to-head clinical analysis: PANTOPAQUE versus SCANLUX 300.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PANTOPAQUE versus SCANLUX 300.
PANTOPAQUE vs SCANLUX-300
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pantopaque is an iodinated oil-based contrast agent that attenuates X-rays, allowing visualization of the subarachnoid space during myelography. It acts as a positive contrast medium by increasing the absorption of X-rays in the cerebrospinal fluid.
SCANLUX-300 (gadoxetate disodium) is a hepatobiliary MRI contrast agent that shortens T1 relaxation time, enhancing signal intensity in tissues. It is taken up by hepatocytes via OATP1B1/1B3 transporters and excreted into bile via MRP2, allowing both dynamic and hepatobiliary phase imaging.
Adults: 5-15 mL (6-18 g iophendylate) intrathecally for myelography via lumbar puncture. No repeated dosing.
30 mg/m² IV over 1 hour every 4 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 6 hours in patients with normal renal function. In renal impairment, half-life is significantly prolonged (up to 24–48 hours in severe impairment), requiring dose adjustment or avoidance.
Terminal elimination half-life is 3.5 hours (range 2.8–4.5 h); may be prolonged in hepatic impairment (up to 7 h).
Primarily renal (glomerular filtration) with approximately 60-70% of the dose excreted unchanged in urine within 24 hours. Biliary/fecal excretion accounts for less than 5% of the administered dose; minor metabolism occurs, but the majority is eliminated unchanged via kidneys.
Renal excretion of unchanged drug accounts for approximately 30% of the administered dose; fecal/biliary elimination accounts for about 60% (via hepatobiliary secretion into feces); minimal excretion via other routes.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent